The Heart Failure Research team of Prof.dr.Stephane Heymans within CARIM and the University (Hospital) of Maastricht (www.hfresearch.eu) is looking for a(MD) PhD candidates to to identify the best immune/genetic targets of non-ischemic cardiomyopathies. If you are interested in identifying new therapeutic traget by working with iPSc cells and animal models of our genetic cardiomyopathy patients, you will like this project. Focus will be on the titin truncating variants. If you have expertise in histology, in vitro iPSc and in vivo animal work, esp. heart failure, you will be able to have a very quick start . A strong opportunity will be the collaboration with clinical researchers and industry partners to validate your iPSc and animal data in the transcriptomics (cardiac samples) and clinical data of patients with the same underlying genetic (titin tv) cardiac disease. (
www.hfresearch.eu)
Projects: we have 2 positions available, within International (European) projects in close collaboration with industry/clinics.
Environment.
This team has a strong combined clinical-translational-basic research expertise in nonischemic (genetic & inflammatory) cardiomyopathies, with deep phenotyped patient cohort (follow up of up to 20 years); with iPSc, DNA, plasma/serum, and cardiac tissue biobanking, and a long-term clinical and imaging follow-up. Our team exists of enthousiastic clinical and basic researchers/ technicians. As such you will understand what the impact of your work is for the patient behind it. We have indeed mouse models and iPSc cells available to identify validate the targets in (titin) genetic cardiomyopathy. We have transcriptomics and whole genome sequencing data available in >300 cardiomyopathy patients. Along your iPSc and animal work in titin genetic cardiomyophaty, these molecular and clinical data in patients will help not only to unveal but also validate the mechanisms of specific genetic heart failure, and iselect the best targets to be validated again in mouse/iPSc model. You will have the opportunity to closely work together with clinicians and industry partners (Pharma and Biotech) to bring it further into the patient.